Literature DB >> 27658780

HOX genes: potential candidates for the progression of laryngeal squamous cell carcinoma.

Rafaela de Barros E Lima Bueno1,2, Anelisa Ramão1,2, Daniel Guariz Pinheiro3, Cleidson Padua Alves2,4, Vinicius Kannen5, Achim A Jungbluth6, Luiza Ferreira de Araújo1,2,4, Bruna Rodrigues Muys1,2, Aline Simoneti Fonseca1,2,4, Jessica Rodrigues Plaça2,4, Rodrigo Alexandre Panepucci2, Luciano Neder5, Fabiano P Saggioro5, Rui Celso M Mamede7, David Livingstone Alves Figueiredo8, Wilson Araújo Silva9,10,11,12.   

Abstract

Laryngeal squamous cell carcinoma (LSCC) is a very aggressive cancer, considered to be a subtype of the head and neck squamous cell carcinoma (HNSCC). Despite significant advances in the understanding and treatment of cancer, prognosis of patients with LSCC has not improved recently. In the present study, we sought to understand better the genetic mechanisms underlying LSCC development. Thirty-two tumor samples were collected from patients undergoing surgical resection of LSCC. The samples were submitted to whole-genome cDNA microarray analysis aiming to identify genetic targets in LSCC. We also employed bioinformatic approaches to expand our findings using the TCGA database and further performed functional assays, using human HNSCC cell lines, to evaluate viability, cell proliferation, and cell migration after silencing of selected genes. Eight members of the homeobox gene family (HOX) were identified to be overexpressed in LSCC samples when compared to normal larynx tissue. Quantitative RT-PCR analysis validated the overexpression of HOX gene family members in LSCC. Receiver operating characteristic (ROC) statistical method curve showed that the expression level of seven members of HOX gene family can distinguish tumor from nontumor tissue. Correlation analysis of clinical and gene expression data revealed that HOXC8 and HOXD11 genes were associated with the differentiation degree of tumors and regional lymph node metastases, respectively. Additionally, siRNA assays confirmed that HOXC8, HOXD10, and HOXD11 genes might be critical for cell colony proliferation and cell migration. According to our findings, several members of the HOX genes were overexpressed in LSCC samples and seem to be required in biological processes involved in tumor development. This suggests that HOX genes might play a critical role in the physiopathology of LSCC tumors.

Entities:  

Keywords:  Cell migration; Gene regulation; HOX genes; Larynx squamous cell carcinoma

Mesh:

Substances:

Year:  2016        PMID: 27658780     DOI: 10.1007/s13277-016-5356-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  27 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Identification of 20 genes aberrantly methylated in human breast cancers.

Authors:  Kazuaki Miyamoto; Takashi Fukutomi; Sadako Akashi-Tanaka; Tadashi Hasegawa; Toshimasa Asahara; Takashi Sugimura; Toshikazu Ushijima
Journal:  Int J Cancer       Date:  2005-09-01       Impact factor: 7.396

Review 3.  The Hox genes and their roles in oncogenesis.

Authors:  Nilay Shah; Saraswati Sukumar
Journal:  Nat Rev Cancer       Date:  2010-04-01       Impact factor: 60.716

4.  The survival predictive significance of HOXC6 and HOXC8 in esophageal squamous cell carcinoma.

Authors:  Ya-Bing Du; Bin Dong; Lu-Yan Shen; Wan-Pu Yan; Liang Dai; Hong-Chao Xiong; Zhen Liang; Xiao-Zheng Kang; Bin Qin; Ke-Neng Chen
Journal:  J Surg Res       Date:  2014-01-17       Impact factor: 2.192

Review 5.  The molecular pathogenesis of head and neck squamous cell carcinoma.

Authors:  S Michael Rothenberg; Leif W Ellisen
Journal:  J Clin Invest       Date:  2012-06       Impact factor: 14.808

6.  Expression of HOXD10 gene in normal endometrium and endometrial adenocarcinoma.

Authors:  J Osborne; C Hu; C Hawley; L J Underwood; T J O'Brien; V V Baker
Journal:  J Soc Gynecol Investig       Date:  1998 Sep-Oct

7.  Gene expression analysis of laryngeal squamous cell carcinoma.

Authors:  Jessica Rodrigues Plaça; Rafaela de Barros E Lima Bueno; Daniel Guariz Pinheiro; Rodrigo Alexandre Panepucci; Luiza Ferreira de Araújo; Rui Celso Martins Mamede; David Livingstone Alves Figueiredo; Wilson Araújo Silva
Journal:  Genom Data       Date:  2015-05-08

8.  Retrospective analysis of prognostic factors in 205 patients with laryngeal squamous cell carcinoma who underwent surgical treatment.

Authors:  Si-Yi Zhang; Zhong-Ming Lu; Xiao-Ning Luo; Liang-Si Chen; Ping-Jiang Ge; Xin-Han Song; Shao-Hua Chen; Yi-Long Wu
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

9.  POU2F1 activity regulates HOXD10 and HOXD11 promoting a proliferative and invasive phenotype in head and neck cancer.

Authors:  Daniel J Sharpe; Katy S Orr; Michael Moran; Sharon J White; Stephen McQuaid; Terence R Lappin; Alexander Thompson; Jacqueline A James
Journal:  Oncotarget       Date:  2014-09-30

10.  TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data.

Authors:  Antonio Colaprico; Tiago C Silva; Catharina Olsen; Luciano Garofano; Claudia Cava; Davide Garolini; Thais S Sabedot; Tathiane M Malta; Stefano M Pagnotta; Isabella Castiglioni; Michele Ceccarelli; Gianluca Bontempi; Houtan Noushmehr
Journal:  Nucleic Acids Res       Date:  2015-12-23       Impact factor: 16.971

View more
  8 in total

1.  Downregulated cytoplasmic polyadenylation element-binding protein-4 is associated with the carcinogenesis of head and neck squamous cell carcinoma.

Authors:  Manli Zeng; Fen Li; Lei Wang; Chen Chen; Xiaolin Huang; Xingyu Wu; Wensheng She; Lin Zhou; Zezhang Tao
Journal:  Oncol Lett       Date:  2017-12-20       Impact factor: 2.967

2.  Identification of core biomarkers associated with pathogenesis and prognostic outcomes of laryngeal squamous-cell cancer using bioinformatics analysis.

Authors:  Wei Chen; Lianming Liao; Haichun Lai; Xuehan Yi; Desheng Wang
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-02-17       Impact factor: 2.503

3.  HOXB9 Expression Correlates with Histological Grade and Prognosis in LSCC.

Authors:  Chuanhui Sun; Changsong Han; Peng Wang; Yinji Jin; Yanan Sun; Lingmei Qu
Journal:  Biomed Res Int       Date:  2017-07-20       Impact factor: 3.411

4.  miR-224 enhances invasion and metastasis by targeting HOXD10 in non-small cell lung cancer cells.

Authors:  Shuang Li; Jingang Zhang; Yunwei Zhao; Fengling Wang; Ying Chen; Xiubin Fei
Journal:  Oncol Lett       Date:  2018-03-12       Impact factor: 2.967

5.  Identification of ESM1 overexpressed in head and neck squamous cell carcinoma.

Authors:  Hongbo Xu; Xiaohong Chen; Zhigang Huang
Journal:  Cancer Cell Int       Date:  2019-05-02       Impact factor: 5.722

6.  A predictive and prognostic model for hepatocellular carcinoma with microvascular invasion based TCGA database genomics.

Authors:  Jin Wang; Zhi-Wen Ding; Kuang Chen; Yan-Zhe Liu; Nan Li; Ming-Gen Hu
Journal:  BMC Cancer       Date:  2021-12-16       Impact factor: 4.430

7.  The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.

Authors:  Charlie E Massie; Andy G Lynch; Rosalind A Eeles; Colin S Cooper; David C Wedge; Daniel S Brewer; Claudia Buhigas; Anne Y Warren; Wing-Kit Leung; Hayley C Whitaker; Hayley J Luxton; Steve Hawkins; Jonathan Kay; Adam Butler; Yaobo Xu; Dan J Woodcock; Sue Merson; Fiona M Frame; Atef Sahli; Federico Abascal; Iñigo Martincorena; G Steven Bova; Christopher S Foster; Peter Campbell; Norman J Maitland; David E Neal
Journal:  Mol Cancer       Date:  2022-09-22       Impact factor: 41.444

8.  Abnormal expression of HOXD11 promotes the malignant behavior of glioma cells and leads to poor prognosis of glioma patients.

Authors:  Jialin Wang; Zhendong Liu; Cheng Zhang; Hongbo Wang; Ang Li; Binfeng Liu; Xiaoyu Lian; Zhishuai Ren; Wang Zhang; Yanbiao Wang; Bo Zhang; Bo Pang; Yanzheng Gao
Journal:  PeerJ       Date:  2021-02-08       Impact factor: 2.984

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.